Treatment options in lymph node-positive prostate cancer

Gregory P. Swanson, Ian M. Thompson, Joseph Basler

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


With improved awareness and screening, the incidence of lymph node-positive prostate cancer has declined dramatically over the last 50 years. Stage of cancer, prostate-specific antigen, and grade are risk factors for positive lymph nodes; and those factors, along with the number of involved lymph nodes, are prognostic factors for outcome. Although the numbers have declined, the number of men with lymph node-positive prostate cancer remains significant, and the current challenge is how best to treat these patients. Commonly used treatments include any combination of androgen ablation, surgery, and radiation. There have been a few studies with chemotherapy, and no treatment has been proven superior to the others. Consequently, there remain several reasonable alternatives to treatment, and long-term survival is not unusual.

Original languageEnglish (US)
Pages (from-to)2531-2539
Number of pages9
Issue number12
StatePublished - Jun 15 2006


  • Androgen ablation
  • Lymph node positive
  • Orchiectomy
  • Prostate-specific antigen
  • Radiation
  • Radical prostotectomy
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment options in lymph node-positive prostate cancer'. Together they form a unique fingerprint.

Cite this